DiaMedica Therapeutics announced that Health Canada has granted a No Objection Letter, allowing the company to begin enrolling patients in the Canadian portion of its Phase 2 study of DM199, a recombinant kallikrein‑1 candidate, for early‑onset preeclampsia.
The open‑label, dose‑ranging trial will evaluate safety, tolerability and exploratory efficacy markers in women between 24 and 32 weeks of gestation. The study builds on encouraging interim data from Part 1a of the Phase 2 program, which was released in July 2025 and showed statistically significant reductions in systolic and diastolic blood pressure without placental transfer of the drug.
Management highlighted the significance of the clearance, noting that it “represents an important regulatory milestone for DiaMedica. This clearance allows us to launch our planned Phase 2 PE study to build upon the encouraging results observed in the investigator‑sponsored trial in South Africa. We look forward to continuing our work to bring a clinically meaningful therapeutic option for women suffering from early‑onset preeclampsia, a patient population with significant unmet medical need and no currently approved treatment options.”
Preeclampsia is a serious pregnancy‑related condition with no approved pharmacologic therapy; the market is projected to reach $4.2 billion by 2033. DM199’s mechanism—restoring vascular health through increased nitric oxide, prostacyclin and endothelium‑derived hyperpolarizing factor—positions it as a first‑in‑class treatment that could transform care for this high‑risk population.
The Canadian launch is a key step toward expanding the global study into the United States and the United Kingdom once additional regulatory approvals are obtained. DiaMedica also continues development of DM199 for acute ischemic stroke and of DM300 for severe acute pancreatitis, broadening its pipeline beyond preeclampsia.
The company’s market capitalization is approximately $400 million, and the Health Canada clearance is expected to strengthen investor confidence in the company’s ability to navigate regulatory pathways and generate pivotal data for its flagship program.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.